Industry Tightens Drug Pricing Message, But Loose Ends Remain

Drug makers are under increasing pressure regarding the cost of their medicines, but instead of pointing fingers at payers for patients' out-of-pocket costs, the industry has shifted to a more collaborative tone, although some tensions will take time to overcome.

Bottles

The biopharma industry is headed in the right direction when it comes to talking about drug pricing, moving from a discussion about how much money is invested in research and development to a dialog with other stakeholders involved in delivering, paying for and benefitting from new medicines.

Scrip attended panel discussions about drug value, pricing and access, and interviewed drug company executives about the topic during the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip